Home / Sweden / Hansa Biopharma AB
Hansa Biopharma AB
Short position disclosed on September 24, 2026.
Evolution of the disclosed total
January 15, 2019 today
Open positions
| Fund | Twelve months | % of capital | Over the year | Since |
|---|---|---|---|---|
| ActusRayPartners Limited | 0.90% | +0.30 pt | August 28, 2026 | |
| Worldquant LLC | 0.64% | +0.06 pt | September 24, 2026 | |
| GSA Capital Partners LLP | 0.60% | +0.06 pt | September 9, 2026 | |
| D E Shaw Co LP | 0.50% | new | September 24, 2026 |
In the United States HNSBF (OTC): 25,732 shares sold short on September 15, 2026. FINRA names no fund.
On the other side: the funds that hold Hansa Biopharma AB Titelia
Get the moves on Hansa Biopharma AB by mail.
There is no account to create. You give an address, you confirm it through a link, and every message contains a link to stop.
History of disclosures
Download 434 filings as CSV Columns: Date, Fund, Market, Disclosed position, Unit, End date. The other formats
Other companies sold short in Sweden
- Samhällsbyggnadsbolaget i Norden AB 12.10% of the capital sold short
- Elekta AB (publ) 9.31% of the capital sold short
- JM AB 7.21% of the capital sold short
- Bonesupport Holding AB 6.91% of the capital sold short
- Truecaller AB 6.88% of the capital sold short
- Hemnet Group AB (publ) 5.63% of the capital sold short
- Xvivo Perfusion Aktiebolag 5.41% of the capital sold short
- Dynavox Group AB 5.38% of the capital sold short
- RaySearch Laboratories AB (publ) 4.96% of the capital sold short
- Aktiebolaget Electrolux 4.41% of the capital sold short
- AAK AB (publ) 4.31% of the capital sold short
- Hexatronic Group AB 3.77% of the capital sold short
Cite this page
The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.
QuiVad, Hansa Biopharma AB, source Finansinspektionen, data as at September 24, 2026, https://www.quivad.com/action/hansa-biopharma-ab?page=7